Literature DB >> 35363371

Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19.

H-F Wei1, S Anchipolovsky, R Vera, G Liang, D-M Chuang.   

Abstract

Disruption of intracellular Ca2+ homeostasis plays an important role as an upstream pathology in Alzheimer's disease (AD), and correction of Ca2+ dysregulation has been increasingly proposed as a target of future effective disease-modified drugs for treating AD. Calcium dysregulation is also an upstream pathology for the COVID-19 virus SARS-CoV-2 infection and replication, leading to host cell damage. Clinically available drugs that can inhibit the disturbed intracellular Ca2+ homeostasis have been repurposed to treat COVID-19 patients. This narrative review aims at exploring the underlying mechanism by which lithium, a first line drug for the treatment of bipolar disorder, inhibits Ca2+ dysregulation and associated downstream pathology in both AD and COVID-19. It is suggested that lithium can be repurposed to treat AD patients, especially those afflicted with COVID-19.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35363371      PMCID： PMC9173589          DOI： 10.26355/eurrev_202203_28369

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN： 1128-3602            Impact factor:   3.784


  232 in total

Review 1.  Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders.

Authors:  M P Mattson; F M LaFerla; S L Chan; M A Leissring; P N Shepel; J D Geiger
Journal:  Trends Neurosci       Date:  2000-05       Impact factor: 13.837

Review 2.  Altered Metabolism in Alzheimer Disease Brain: Role of Oxidative Stress.

Authors:  Nicole G Rummel; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2021-12-21       Impact factor: 7.468

Review 3.  Lithium neuroprotection: molecular mechanisms and clinical implications.

Authors:  Michael K Rowe; De-Maw Chuang
Journal:  Expert Rev Mol Med       Date:  2004-10-18       Impact factor: 5.600

4.  Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study

Authors:  Lowell Ling; Christina So; Hoi Ping Shum; Paul K S Chan; Christopher K C Lai; Darshana H Kandamby; Eunise Ho; Dominic So; Wing Wa Yan; Grace Lui; Wai Shing Leung; Man Chun Chan; Charles D Gomersall
Journal:  Crit Care Resusc       Date:  2020-04-06       Impact factor: 2.159

5.  Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.

Authors:  Patricia Spilman; Natalia Podlutskaya; Matthew J Hart; Jayanta Debnath; Olivia Gorostiza; Dale Bredesen; Arlan Richardson; Randy Strong; Veronica Galvan
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

6.  [Lithium and its protective effect in Alzheimer's disease].

Authors:  S M Wittenberg; K A Toxopeus; P F J Schulte
Journal:  Tijdschr Psychiatr       Date:  2017

Review 7.  The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.

Authors:  Yan-Chao Li; Wan-Zhu Bai; Tsutomu Hashikawa
Journal:  J Med Virol       Date:  2020-03-11       Impact factor: 2.327

8.  Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19.

Authors:  Isaac Solaimanzadeh
Journal:  Cureus       Date:  2020-05-12

Review 9.  Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease.

Authors:  Amy F T Arnsten; Dibyadeep Datta; Kelly Del Tredici; Heiko Braak
Journal:  Alzheimers Dement       Date:  2020-10-19       Impact factor: 16.655
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.